Toggle Nav

Temozolomide

Catalog No.
B1399
DNA methylating, chemotherapeutic agent
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$50.00
In stock
10mg
$50.00
In stock
50mg
$70.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Temozolomide, an alkylating agent, is a DNA damage inducer.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt194.15
Cas No.85622-93-1
FormulaC6H6N6O2
Solubility≥29.61mg/mL in DMSO
Chemical Name3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
SDFDownload SDF
Canonical SMILESCN1C(=O)N2C=NC(=C2N=N1)C(=O)N
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Protocol

Cell experiment [1]:

Cell lines

SK-LMS-1 leiomyosarcoma (MGMT-/p53+), Ewing sarcoma A-673 and GIST-T1 (both lines with MGMT+/p53- phenotype), and glioblastoma T98G (MGMT+/p53+)

Preparation method

The solubility of this compound in DMSO is >6.6mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

62.5, 125, 250 and 500 μM; 72 h

Applications

In SK-LMS-1 cells, Temozolomide inhibited proliferative activity of SK-LMS-1 cells. A-673 cells was most sensitive to temozolomide, the effect was time- and dose-dependent. Preincubation of Ewing sarcoma cells with O6-benzylguanine potentiated the cytotoxic effect of the alkylating agent and reduced viability of tumor cells. GIST-T1 cells were insensitive to temozolomide.

Animal experiment [2]:

Animal models

PARP1 wild‐type (WT) and PARP1 knock‐out (KO) mice

Dosage form

68 mg/kg; once daily for 5 days; orally administrated

Application

In PARP1 WT mice, temozolomide significantly lowered concentrations of NAD+ in the liver when compared with the control group (by 22%, p = 0.02). In the livers of PARP1 KO mice, there was also a statistically significant reduction in NAD+ in the temozolomide‐only group when compared with the control (by 22%, p = 0.03).

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Khusnutdinov RR1, Boichuk SV2. Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide. Bull Exp Biol Med. 2017 Jul 18.

[2]. Almeida GS1, Bawn CM1, Galler M1, et al. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR Biomed. 2017 May 22.

Quality Control